Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | FPR3 | P25089 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786987 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL663588 | 0.76 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ALMNAHTT | |
| SCHEMBL1072758 | 0.74 | — | — | |
| SCHEMBL1518409 | 0.71 | — | — | |
| SCHEMBL662639 | 0.70 | AKR1B1 (0.31) | — | |
| SCHEMBL1684422 | 0.70 | MEN1 (0.55) | ALDH1A1MEN1KMT2ALMNAMME | |
| SCHEMBL17468496 | 0.68 | OPRM1 (0.40) | ALDH1A1MEN1KMT2ALMNAHTT | |
| SCHEMBL662367 | 0.67 | PPARA (0.34) | ALDH1A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL18190832 | 0.66 | CNR2 (0.45) | MEN1KMT2ALMNANPSR1 | |
| SCHEMBL1785684 | 0.66 | HSD11B1 (0.41) | ALDH1A1MEN1KMT2AFPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | ALDH1A1 3500/4885MEN1 4865/4885KMT2A 3867/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | ALDH1A1 4254/4885MEN1 4375/4885KMT2A 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.